Alpine immune sciences, inc. (ALPN)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Collaboration revenue

1,091

884

289

567

0

0

0

390

315

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue

-

-

-

-

-

-

-

-

-

-

128

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue

-

-

-

-

-

-

-

-

-

-

-

738

737

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

737

-

-

-

-

-

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

0

0

0

-

-

-

-

Operating expenses:
Research and development

4,878

5,799

9,532

10,166

10,350

8,931

10,529

5,718

3,792

3,710

2,750

2,308

1,858

5,656

819

6,424

5,567

4,293

4,279

4,465

3,017

2,822

2,164

3,363

3,851

General and administrative

1,778

2,102

2,467

2,553

2,345

2,514

1,857

1,883

2,108

1,207

1,932

2,067

873

2,168

299

2,172

2,367

2,337

1,822

1,387

1,298

664

490

594

539

Loss on sale of intangible asset

-

-

0

0

-

-

0

-1,203

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

6,656

7,901

11,999

12,719

12,695

11,445

12,386

8,804

5,900

4,917

4,682

4,375

2,731

-

1,118

-

-

-

-

-

-

-

-

-

-

Restructuring charges

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

0

0

0

-

-

-

-

Loss from operations

-5,565

-7,017

-11,710

-12,152

-12,695

-11,445

-12,386

-8,414

-5,585

-4,789

-4,554

-3,637

-1,994

-7,824

-381

-8,596

-7,934

-6,630

-6,101

-5,852

-4,315

-3,486

-2,654

-3,957

-4,390

Other income (expense):
Business Combination, Bargain Purchase, Gain Recognized, Amount

-

-

-

-

-

-

-

-

-

-

6,539

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

111

-

117

96

67

12

0

1

-

-

-

-

Interest and other income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

35

9

252

Interest expense

120

141

66

61

70

76

82

83

78

76

75

1

0

0

-

-

0

0

0

0

0

0

392

241

212

Interest income

152

-

301

357

384

-

329

337

305

-

216

40

5

-

7

-

-

-

-

-

-

-

-

-

-

Loss before taxes

-

-

-11,475

-11,856

-

-11,196

-12,139

-8,160

-5,358

-4,522

2,126

-3,598

-1,989

-

-374

-

-

-

-

-

-

-

-

-

-

Income Tax Expense (Benefit)

-

-

0

0

-

-61

0

-253

-52

-204

4

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,011

-4,189

-4,350

Gain on extinguishment of convertible debt as a capital transaction

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

378

-

-

Net loss

-5,533

-6,140

-11,475

-11,856

-12,381

-11,135

-12,139

-7,907

-5,306

-4,318

2,122

-3,598

-1,989

-7,713

-374

-8,479

-7,838

-6,563

-6,089

-5,852

-4,314

-3,864

-2,633

-4,189

-4,350

Comprehensive income (loss):
Unrealized (loss) gain on investments

-15

-8

5

17

15

12

30

50

-46

-47

-12

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized loss on foreign currency translation

-113

-

-7

-

-14

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other Comprehensive Income (Loss), Foreign Currency Translation Gain (Loss) Arising During Period, Tax

-

-

-

-4

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,838

-

-

-

-

-

-

-

-

Unrealized gains (losses) on marketable securities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20

-

-

-

-

-

-

-

-

-

Comprehensive loss

-5,661

-6,137

-11,477

-11,835

-12,380

-11,123

-12,109

-7,857

-5,352

-4,365

2,110

-3,598

-1,989

15,439

-374

-8,459

-7,838

-

-

-

-

-

-

-

-

Weighted-average shares used to compute basic net income (loss) per share attributable to common stockholders (in shares)

-

-

-

-

-

-

-

-

-

-

10,577

-

-

-

608

-

-

-

-

-

-

-

-

-

-

Basic net income (loss) per share attributable to common stockholders (in dollars per share)

-

-

-

-

-

-

-

-

-

-

0.20

-

-

-

-0.61

-

-

-

-

-

-

-

-

-

-

Weighted-average shares used to compute diluted net income (loss) per share attributable to common stockholders (in shares)

-

-

-

-

-

-

-

-

-

-

11,586

-

-

-

608

-

-

-

-

-

-

-

-

-

-

Diluted net income (loss) per share attributable to common stockholders (in dollars per share)

-

-

-

-

-

-

-

-

-

-

0.18

-

-

-

-0.61

-

-

-

-

-

-

-

-

-

-

Weighted-average shares used to compute basic and diluted net loss per share (in shares)

18,587

18,600

18,586

18,576

17,671

13,852

13,851

13,848

13,844

-

-

666

615

15,540

-

15,462

15,462

15,452

15,451

4,159

2,209

2,891

0

0

0

Basic and diluted net loss per share (in dollars per share)

-0.30

-0.32

-0.62

-0.64

-0.70

-0.80

-0.88

-0.57

-0.38

-

-

-5.40

-3.23

-0.50

-

-0.55

-0.51

-0.42

-0.39

-1.41

-1.95

40.13

-7.68

-25.70

-27.02

Total stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

700

707

-

-

-

-

-

-

-

-